352 related articles for article (PubMed ID: 30667591)
1. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
[TBL] [Abstract][Full Text] [Related]
2. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
[TBL] [Abstract][Full Text] [Related]
4. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
[TBL] [Abstract][Full Text] [Related]
5. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
[TBL] [Abstract][Full Text] [Related]
7. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
8. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
[TBL] [Abstract][Full Text] [Related]
10. De novo tacrolimus extended-release tablets (LCPT) versus twice-daily tacrolimus in adult heart transplantation: Results of a single-center non-inferiority matched control trial.
van Zyl JS; Sam T; Clark DM; Felius J; Doss AK; Kerlee KR; Cheung ZO; Martits-Chalangari K; Jamil AK; Carey SA; Gottlieb RL; Guerrero-Miranda CY; Kale P; Hall SA
Clin Transplant; 2021 Dec; 35(12):e14487. PubMed ID: 34529289
[TBL] [Abstract][Full Text] [Related]
11. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.
Gaber AO; Alloway RR; Bodziak K; Kaplan B; Bunnapradist S
Transplantation; 2013 Jul; 96(2):191-7. PubMed ID: 23715050
[TBL] [Abstract][Full Text] [Related]
12. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
[TBL] [Abstract][Full Text] [Related]
13. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
[TBL] [Abstract][Full Text] [Related]
14. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
Transpl Int; 2022; 35():10225. PubMed ID: 36017158
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study.
Bilbao I; Gómez Bravo MÁ; Otero A; Lladó L; Montero JL; González Dieguez L; Graus J; Pons Miñano JA
Clin Transplant; 2023 Dec; 37(12):e15105. PubMed ID: 37615653
[TBL] [Abstract][Full Text] [Related]
17. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
Shin MH; Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Yun YI; Kim WJ; Kang WH; Kim SH; Jiang H; Lee S; Tak EY
Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended-Release Once-Daily Tacrolimus Tablets.
Philosophe B; Leca N; West-Thielke PM; Horwedel T; Culkin-Gemmell C; Kistler K; Stevens DR
J Clin Pharmacol; 2018 Jul; 58(7):891-896. PubMed ID: 29462506
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients.
Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC
J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial.
Fischer L; Trunečka P; Gridelli B; Roy A; Vitale A; Valdivieso A; Varo E; Seehofer D; Lynch S; Samuel D; Ericzon BG; Boudjema K; Karpf C; Undre N
Liver Transpl; 2011 Feb; 17(2):167-77. PubMed ID: 21280190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
